Author： Verhoef Talitha I Redekop William K van Schie Rianne MF Bayat Samira Daly Ann K Geitona Mary Haschke-Becher Elisabeth Hughes Dyfrig A Kamali Farhad Levin Lars-Åke Manolopoulos Vangelis G Pirmohamed Munir Siebert Uwe Stingl Julia C Wadelius Mia de Boer Anthonius Maitland-van der Zee Anke-Hilse
Publisher： Future Medicine
ISSN： 1462-2416
Source： Pharmacogenomics, Vol.13, Iss.12, 2012-09, pp. : 1405-1417
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
Estimating `Costs' for Cost-Effectiveness Analysis
By Miners Alec
PharmacoEconomics, Vol. 26, Iss. 9, 2008-01 ,pp. :
Access to resources
Recommend
Cost-Effectiveness Analysis in Markets with High Fixed Costs
By Cutler David M. Ericson Keith M. Marzilli
PharmacoEconomics, Vol. 28, Iss. 10, 2010-10 ,pp. :
Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 7, Iss. 4, 2009-12 ,pp. :
Cost–effectiveness analysis in pharmacogenomics
By Payne Katherine Shabaruddin Fatiha H
Pharmacogenomics, Vol. 11, Iss. 5, 2010-05 ,pp. :